<DOC>
	<DOC>NCT00152620</DOC>
	<brief_summary>The aim of this therapeutic trial is to compare the response of subjects with active IBD to daily intravenous dexamethasone versus the response to daily intravenous methylprednisolone.</brief_summary>
	<brief_title>Dexamethasone Versus Methylprednisolone for the Treatment of Active Inflammatory Bowel Disease</brief_title>
	<detailed_description />
	<mesh_term>Intestinal Diseases</mesh_term>
	<mesh_term>Inflammatory Bowel Diseases</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Parental informed consent Subjects 6 to 19 years of age with confirmed diagnosis of IBD (Crohn's disease, ulcerative colitis or indeterminate colitis), who on admission to the hospital have a PCDAI&gt;15 or a ClinicalActivity Index for the Evaluation of Patients with Ulcerative Colitis of &gt;10. Infectious causes (viruses, bacteria, parasites) have been ruled out. Subjects in which the administration of corticosteroids would be contraindicated such as systemic or enteric infections diagnosed by stool analysis including culture, Clostridium Difficile toxin assay, rotavirus or adenovirus 40/41 antigens. Subjects with enterostomy or colostomy Subjects with one or more of the following conditions: unstable vital signs, acute abdomen, toxic megacolon, intestinal obstruction, intestinal perforation</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>19 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Inflammatory Bowel Disease (IBD)</keyword>
</DOC>